CTRI/2021/09/036551CompletedPhase 3
A randomized, double blind, parallel assignment, placebo-controlled, two arm study to evaluate the safety and efficacy of iGlow (poly herbal preparation) on overall skin health among healthy adult volunteers
IndusViva HealthSciences Pvt Ltd0 sites90 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Enrollment
- 90
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •1.Subjects in generally good health
- •2.Subjects age group 18 - 55 years
- •3.Subjects willing to follow the suggested diet plan.
- •4.Subjects willing to give a written informed consent and come for a regular follow up
- •5.Subject willing to abide by and comply with the study protocol
- •6.Subject has not participated in a similar investigation in the past four weeks.
- •7.Subjects having visible fine lines and wrinkles in periorbital area (Crowââ?¬•s feet), nasolabial areas, forehead , and perioral regions of the face
- •8.Subjects having mild to moderate naso-labial folds
- •9.Subjects having apparent mild to moderate crowââ?¬•s feet in unanimated face
- •10.Subjects who have not under gone any facial anti-ageing
- •procedures (e.g.Botulinum dermal filler injections, laser resurfacing) in the past 3 months.
- •11.Subject should be willing to abstain from spa treatments/facials during the study period
Exclusion Criteria
- •1.A known history or present condition of allergic response to any cosmetic products.
- •2.Subjects having severe photo-aging.
- •3.Subject having skin diseases (e.g. moderate to severe acne vulgaris face or nodulocystic acne, psoriasis, active atopic dermatitis, melasma, lichen planus pigmentosus/ Achy dermatosis, pigmented contact dermatitis or other cutaneous manifestations), which will interfere with the test readings.
- •4.Subjects on oral medications (e.g. steroids, anti-oxidant) or any skin supplement for skin care which will compromise the study.
- •5.Systemic treatment which may modify the cutaneous state on the day of inclusion or in the previous 30 days, including retinoid therapy.
- •6.Subjects not willing to discontinue other topical anti-ageing, anti- wrinkle facial products.
- •7.Subjects who are pregnant, lactating or nursing.
- •8.Hypersensitivity to any component of the tested products.
- •9.History of intense sun exposure.
- •10.Chronic illness which may influence the cutaneous state.
- •11.Subject participating in any other cosmetic or therapeutic trial.
- •12.Any underlying uncontrolled medical illness including diabetes mellitus, hypertension, liver disease or history of alcoholism, HIV, hepatitis, or any other serious medical illness
Investigators
Similar Trials
Completed
Phase 3
Clinical trial on overweight adult healthy volunteersCTRI/2021/02/031066IndusViva HealthSciences Pvt Ltd80
Completed
Unknown
Randomized assignment, double-blind, parallel design, placebo-controlled human application test to evaluate the effectiveness and safety of erythema complexes on the excrement of ingested fatEndocrine, nutritional and metabolic diseasesKCT0008815B&Tech70
Active, not recruiting
Not Applicable
A randomised, double blind, double-dummy, parallel group study to compare the efficacy and tolerability of morphine sulphate prolonged release capsules and methadone oral solution in once per day administration for agonist maintenance treatment of opiate addiction. - SUB3001EUCTR2005-004482-41-GBapp Pharmaceuticals Research Limited
Active, not recruiting
Not Applicable
Comparison of Flutiform, fluticasone and Seretide in treatment of moderate to severe asthma in paediatric patients aged 5 to less than 12 years.Asthma BronchioleMedDRA version: 16.0Level: LLTClassification code 10003555Term: Asthma bronchialSystem Organ Class: 100000004855EUCTR2010-024635-16-BGMundipharma Research Limited498
Active, not recruiting
Not Applicable
Comparison of Flutiform, fluticasone and Seretide in treatment of moderate to severe asthma in paediatric patients aged 5 to less than 12 years.EUCTR2010-024635-16-PLMundipharma Research Limited498